Valproic Acid Capsule, Liquid Filled
NDC Package 17856-0152-1

11-digit billing NDC: 17856015201 · Billing unit: EA · 100 EA per package

Package Information

Valproic Acid capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1)]. This formulation utilizes a capsule, liquid filled delivery system. Marketed by Atlantic Biologicals Corp., this product is identified by NDC 17856-0152 and is authorized under FDA application ANDA073484.

Identification & Billing

NDC Package Code
17856-0152-1
Package Description
100 POUCH in 1 BOX, UNIT-DOSE / 1 CAPSULE, LIQUID FILLED in 1 POUCH
Product Code
11-Digit Billing Format
17856015201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Valproic Acid
Non-Proprietary Name
Valproic Acid
Substance Name
Valproic Acid
Dosage Form
Capsule, Liquid Filled - A solid dosage form in which the drug is enclosed within a soluble, gelatin shell which is plasticized by the addition of a polyol, such as sorbitol or glycerin, and is therefore of a somewhat thicker consistency than that of a hard shell capsule; typically, the active ingredients are dissolved or suspended in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Valproic Acid Capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions ( 5.1)] . Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions ( 5.1)] . Valproic Acid is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions ( 5.12)] . Valproic Acid is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions ( 5.6)] . For use in prophylaxis of migraine headaches: Valproic Acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception  [see Warnings and Precautions ( 5.2,5.3, 5.4) and Use in Specific Populations (8.1)].

Regulatory & Marketing

Labeler Name
Atlantic Biologicals Corp.
Product Type
Human Prescription Drug
FDA Application #
ANDA073484
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-15-2016
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 17856-0152-1 identifies a specific commercial package of 100 pouch in 1 box, unit-dose / 1 capsule, liquid filled in 1 pouch of Valproic Acid, a human prescription drug labeled by Atlantic Biologicals Corp.. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This capsule, liquid filled is formulated for oral use and contains valproic acid as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Atlantic Biologicals Corp. on July 15, 2016. The current certification is valid through December 31, 2026.

How is this Atlantic Biologicals Corp. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 17856015201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
17856-0152-1
11-Digit CMS (5-4-2)
17856-0152-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.